EXoPERT’s a fully automated liquid biopsy platform enabling early detection (Stage 1–2) of multiple cancers(including lung, ovarian, liver, stomach, and breast) in primary care and public health settings. Unlike conventional biomarker-based methods such as ctDNA or NGS, it analyzes Raman spectral signals from blood-derived extracellular vesicles, detecting subtle molecular changes without complex preprocessing. The system achieves 90.2% sensitivity and 94.4% specificity for early-stage cancer. Its three-step workflow - (1) Exosome isolation, (2) Raman-based molecular fingerprint detection, and (3) AI-driven result interpretation - streamlines diagnostics while cutting labor and reducing per-test costs by over 50%. The automated isolation process further minimizes plastic waste with one cartridge per sample. The platform integrates four proprietary modules (Exo-i, ExoTractor, ARM Dx, and ExoPred) into a compact benchtop system, enabling decentralized screening beyond specialized hospitals. EXoPERT delivers high-accuracy, cost-effective, and eco-conscious cancer detection, offering a practical and scalable solution for public health applications.